ANAB
HEALTHCAREAnaptysBio Inc
$67.36-1.92 (-2.77%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ANAB Today?
No stock-specific AI insight has been generated for ANAB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$11.40$72.36
$67.36
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.46
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume681K
Avg Volume (10D)—
Shares Outstanding29.1M
ANAB News
20 articles- TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewYahoo Finance·May 7, 2026
- Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View RaisedYahoo Finance·May 7, 2026
- AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?Yahoo Finance·May 6, 2026
- Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?Yahoo Finance·May 5, 2026
- Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceYahoo Finance·May 4, 2026
- AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro DisputeYahoo Finance·May 4, 2026
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidenceYahoo Finance·Apr 28, 2026
- AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseYahoo Finance·Apr 27, 2026
- AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?Yahoo Finance·Apr 27, 2026
- GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBioProactive Investors·Apr 27, 2026
- Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach ClaimGlobeNewswire Inc.·Apr 24, 2026
- Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial CollaborationsYahoo Finance·Apr 20, 2026
- Four Biotech Stocks Near Buy Points As Earnings Season Kicks InYahoo Finance·Apr 17, 2026
- Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity OfferingsYahoo Finance·Apr 5, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Mar 27, 2026
- Sector Update: Health Care Stocks Retreat Friday AfternoonYahoo Finance·Mar 27, 2026
- AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million SharesYahoo Finance·Mar 27, 2026
- Anaptys Board of Directors Approves Spin-Off of First Tracks BiotherapeuticsYahoo Finance·Mar 27, 2026
- First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private PlacementYahoo Finance·Mar 27, 2026
- Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business UpdateYahoo Finance·Mar 27, 2026
All 20 articles loaded
Price Data
Open$69.08
Previous Close$69.28
Day High$72.23
Day Low$67.04
52 Week High$72.36
52 Week Low$11.40
52-Week Range
$11.40$72.36
$67.36
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.46
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume681K
Avg Volume (10D)—
Shares Outstanding29.1M
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—